Merck Stock Top Executives

MRK
 Stock
  

USD 87.41  0.59  0.68%   

Merck employes about 67 K people. The company is managed by 52 executives with total tenure of roughly 343 years, averaging almost 6.0 years of service per executive having 1288.46 employees per reported executive. Assessment of Merck management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Merck Company future performance.
Additionally, see Stocks Correlation.
  
  Kenneth Frazier  Chairman
Chairman of the Board, President, Chief Executive Officer
  Michael Rosenblatt  President
Executive Vice President Chief Medical Officer
  Mirian GraddickWeir  President
Executive Vice President - Human Resources

Merck Return on Sales

0.28

Merck Management Team Effectiveness

Merck Company has Return on Asset of 11.73 % which means that on every $100 spent on asset, it made $11.73 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 40.93 %, implying that it generated $40.93 on every 100 dollars invested. Merck management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to increase to 21.07, while Return on Average Assets are projected to decrease to 0.11. The current Total Liabilities is estimated to increase to about 67.8 B. The current Current Liabilities is estimated to increase to about 24.2 B

Merck Quarterly Total Assets

107.09 Billion

The current Weighted Average Shares Diluted is estimated to increase to about 3 B, while Weighted Average Shares is projected to decrease to under 2.5 B.

Merck Workforce Comparison

Merck Company is considered to be number one stock in number of employees category among related companies. The total workforce of Drug Manufacturers—General industry is now estimated at about 962,932. Merck holds roughly 67,000 in number of employees claiming about 7% of equities under Drug Manufacturers—General industry.

Merck Profit Margins

The company has Net Profit Margin of 29.0 %, which may imply that it executes well on its competitive polices and has reasonable control over its expenses and variable costs. This is very large. In the same way, it shows Net Operating Margin of 41.97 %, which entails that for every 100 dollars of revenue, it generated 0.42 of operating income.

Merck Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Merck insiders, such as employees or executives, is commonly permitted as long as it does not rely on Merck's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Merck insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Merck Company Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Merck Company Price Series Summation is a cross summation of Merck price series and its benchmark/peer.
.

Merck Notable Stakeholders

A Merck stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Merck often face trade-offs trying to please all of them. Merck's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Merck's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kenneth Frazier - Chairman of the Board, President, Chief Executive OfficerProfile
Michael Rosenblatt - Executive Vice President Chief Medical OfficerProfile
Caroline Litchfield - Chief Financial Officer, Executive Vice PresidentProfile
Mirian GraddickWeir - Executive Vice President - Human ResourcesProfile
Julie Gerberding - Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population HealthProfile
Franklin Clyburn - President, Human Health, Head of Human Health Commercial and MarketingProfile
Robert Davis - Executive Vice President, Global Services, Chief Financial OfficerProfile
Steven Mizell - Executive Vice President, Chief Human Resources Officer, Human ResourcesProfile
Jim Scholefield - Executive Vice President, Chief Information and Digital OfficerProfile
Sanat Chattopadhyay - Executive Vice President and President - Merck Manufacturing DivisionProfile
Adam Schechter - President of Global Human Health and Executive VPProfile
Cristal Downing - Executive Vice President, Chief Communications, Public Affairs OfficerProfile
Jennifer Zachary - Executive Vice President, General Counsel, Corporate SecretaryProfile
Michael Holston - Executive Vice President Chief Ethics and Compliance OfficerProfile
Adele Ambrose - Senior Vice President Chief Communications OfficerProfile
Willie Deese - Executive Vice President and Presidentident - Merck Manufacturing DivisionProfile
Michael Nally - Executive Vice President, Chief Marketing OfficerProfile
Roger Perlmutter - Executive Vice President and Presidentident - Merck Research LaboratoriesProfile
Ashley Watson - Senior Vice President Chief Ethics and Compliance OfficerProfile
Richard DeLuca - Executive Vice President and Presidentident - Merck Animal HealthProfile
Frank Clyburn - Executive Vice President, Chief Commercial OfficerProfile
Clark Golestani - CIO and Executive VPProfile
Rita Karachun - Principal Accounting Officer, Sr. VP of Fin. and Global ControllerProfile
Rochelle Lazarus - Independent DirectorProfile
Paul Rothman - Independent DirectorProfile
Mary Coe - Independent DirectorProfile
Patricia Russo - Independent DirectorProfile
Robert Kidder - Independent DirectorProfile
Thomas Cech - Independent DirectorProfile
William Harrison - Lead Independent DirectorProfile
Thomas Glocer - Lead Independent DirectorProfile
Craig Thompson - Independent DirectorProfile
Christine Seidman - Independent DirectorProfile
Wendell Weeks - Independent DirectorProfile
Kathy Warden - Independent DirectorProfile
Peter Wendell - Independent DirectorProfile
John Noseworthy - Independent DirectorProfile
Leslie Brun - Lead Independent DirectorProfile
Inge Thulin - Independent DirectorProfile
Pamela Craig - Independent DirectorProfile
Carlos Represas - Independent DirectorProfile
Michael Fleming - Senior Vice President Chief Ethics and Compliance OfficerProfile
Jannie Oosthuizen - Lead - Human Health U.S.Profile
Michael Klobuchar - Executive Vice President Chief Strategy OfficerProfile
David Williams - Executive Vice President Chief Information Chief Information and Digital OfficerProfile
Lisa LeCointeCephas - Senior Vice President Chief Ethics and Compliance OfficerProfile
Deepak Khanna - Lead - Human Health InternationalProfile
Risa LavizzoMourey - Independent DirectorProfile
Arpa Garay - Lead - Human Health Global MarketingProfile
Joseph Romanelli - IR Contact OfficerProfile
Dean Li - Executive Vice President and Presidentident, Merck Research LaboratoriesProfile
Stephen Mayo - Independent DirectorProfile

About Merck Management Performance

The success or failure of an entity such as Merck Company often depends on how effective the management is. Merck management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Merck management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Merck management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Investment 19.53  21.07 
Return on Average Assets 0.14  0.11 
Return on Average Equity 0.39  0.31 
Return on Invested Capital 0.26  0.23 
Return on Sales 0.30  0.28 
Merck Co., Inc. operates as a healthcare company worldwide. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 67000 people.
The data published in Merck's official financial statements usually reflect Merck's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Merck Company. For example, before you start analyzing numbers published by Merck accountants, it's critical to develop an understanding of what Merck's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Merck's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Merck's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Merck's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Merck Company. Please utilize our Beneish M Score to check the likelihood of Merck's management to manipulate its earnings.

Merck Workforce Analysis

Traditionally, organizations such as Merck use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Merck within its industry.

Merck Manpower Efficiency

Return on Merck Manpower

Revenue Per Employee628.9 K
Revenue Per Executive1.1 B
Net Income Per Employee207 K
Net Income Per Executive320 M
Working Capital Per Employee157.6 K
Working Capital Per Executive203.1 M
Today, most investors in Merck Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Merck's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Merck per employee as a starting point in their analysis.

Per Employee

Merck Per Employee Growth Over Time

Net Income Per Employee

207,047

Merck Net Income Per Employee is increasing as compared to previous years. The last year's value of Net Income Per Employee was reported at 191,897

Revenue Per Employee

628,911

Merck Revenue Per Employee is increasing as compared to previous years. The last year's value of Revenue Per Employee was reported at 716,235
Additionally, see Stocks Correlation. Note that the Merck Company information on this page should be used as a complementary analysis to other Merck's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Merck Stock analysis

When running Merck Company price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
1.54
Market Capitalization
221.4 B
Quarterly Revenue Growth YOY
0.28
Return On Assets
0.12
Return On Equity
0.41
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine Merck value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.